Introduction {#s1}
============

Scientific surprises abound in diseases associated with unstable repetitive elements in the DNA, RNA, and proteins. These diseases are caused by expansions or contractions of trinucleotide, tetranucleotide, pentanucleotide, dodecanucleotide, and macrosatellite repeats ([Table 1](#pgen-1002018-t001){ref-type="table"}). This class of disease, including some 40 diseases (for a complete set, see Supplementary [Table 1](#pgen-1002018-t001){ref-type="table"} presented in López Castel et al. [@pgen.1002018-LpezCastel1]), has revealed several unique and unsuspected findings: surprises include mutations that are dynamic---ever changing both through generations and within an individual ([Table 1](#pgen-1002018-t001){ref-type="table"}) [@pgen.1002018-LpezCastel1], [@pgen.1002018-LpezCastel2]. Unsuspected modes of pathogenesis also abound, including: aberrant loss-of-protein expression [@pgen.1002018-LaSpada1]; aberrant over-expression of non-mutant proteins [@pgen.1002018-Pearson1]--[@pgen.1002018-Snider1]; toxic-gain-of-protein function through expanded polyglutamine tracts that are encoded by expanded CAG tracts [@pgen.1002018-LaSpada1]; and RNA-toxic-gain-of-function caused by transcripts harboring expanded CUG or CGG tracts [@pgen.1002018-Shin1], [@pgen.1002018-Oostra1]. There is even one disease known to be caused by both a toxic-polyglutamine and a toxic-RNA, with both arising from bidirectional transcription across both complementary CAG and CTG repeat strands ([Table 1](#pgen-1002018-t001){ref-type="table"}) [@pgen.1002018-Merienne1]--[@pgen.1002018-Batra1]. Many regions of the genome are transcribed across both strands, including most of the repeats associated with disease loci, suggesting that multiple toxic entities (polyGln and toxic CUG-RNAs) may contribute to the pathogenesis of numerous diseases [@pgen.1002018-Merienne1], [@pgen.1002018-Batra1]. How many surprises remain for this field to reveal?

10.1371/journal.pgen.1002018.t001

###### Unstable repeats in DNA, RNA proteins, and human disease.

![](pgen.1002018.t001){#pgen-1002018-t001-1}

  Disease                                                              Gene                  Repeat Unit                   Repeat SizeNormal                       Disease               Bidirectional Transcription                   Mode of Pathogenesis                   RAN-Translation
  -------------------------------------------------------------- ----------------- ------------------------------- ---------------------------------- --------------------------------- ----------------------------- ------------------------------------------------------ -----------------
  HD: Huntington\'s disease                                         *HTT/HTTOS*             (CAG)n•(CTG)n                        10--34                           \>35--250                          Yes                                 PolyGln/GOFRAN?                         CAG?CUG?
  DM1: Myotonic dystrophy type 1                                   *DMPK/DMPKas*            (CTG)n•(CAG)n                        5--37                           \>90--6,550                         Yes                                   CUG/GOFRAN?                           CUGCAG √
  SCA3: Spinocerebellar ataxia 3                                  *ATXN3/ATXN3OS*           (CAG)n•(CTG)n                        13--44                             \>55                             Yes                               PolyGln/CAG/GOFRAN?                       CAG?CUG?
  SCA8: Spinocerebellar ataxia 8                                  *ATXN8/ATXN8OS*           (CTG)n•(CAG)n                        2\>130                             \>110                            Yes                               PolyGln/CUG/GOFRAN?                       CAG √CUG?
  FRDA: Friedreich\'s ataxia                                           *FXN*                (GAA)n•(TTC)n                        6--32                              \>200                            Yes                                       LOF                               GAA?UUC?
  FRAXA: Fragile X syndrome                                         *FMR1/FMR4*             (CGG)n•(CCG)n                        6--52                           230--2,000                          Yes                                     LOFRAN?                             CGG?CCG?
  FXTAS: Fragile X tremor/ataxia syndrome                           *FMR1/FMR4*             (CGG)n•(CCG)n                        6--52                             59--230                           Yes                                   CGG/GOFRAN?                           CGG?CCG?
  DM2: Myotonic dystrophy type 2                                      *ZNF9*               (CCTG)n•(CAGG)n                      104--176                         75--11,000                          No                                   CCGU/GOF?RAN?                            CCUG?
  SCA10: Spinocerebellar ataxia 10                                   *ATXN10*             (ATTCT)n•(AGAAT)n                      10--22                          800--4,500                          No                                   AUUCU/GOFRAN?                      
  SCA31: Spinocerebellar ataxia 31                                  *TK2/BEAN*            (TGGAA)n•(TTCCA)n                        0                                 110                             Yes                                  UGGAA/GOFRAN?                        UGGAA?AGAUU?
  FSHD: Facioscapulohumeral muscular dystrophy                        *DUX4*             3.3 kb D4Z4 repeat                     11--110                             1--10                            Yes               GOF - Over expression of non-mutant proteinRNA? RAN?        RAN?
  Syndromic & non-syndromic X-linked mental retardation (XLMR)         *ARX*          Interrupted(GCG)n•(CGC)n      Tract\# 1(Ala)16Tract\# 2(Ala)12           (Ala)23(Ala)20                         ?                                    PolyAla/GOF                             RAN?
  SPD: Synpolydactyly type II                                        *HOXD13*         Interrupted (GCG)n•(CGC)n                 (Ala)15                          (Ala)22--29                          ?                             Dominant Negative PolyAla                      RAN?
  COMP: Multiple skeletal dysplasias                                                  Interrupted (GAC)n•(GTC)n                  (Asp)5                          (Asp)4,6,7                           ?                                    polyAsp/GOF                             RAN?
  Creutzfeldt-Jakob disease                                           *PRNP*        Interrupted (24 nucleotides)n     (ProHisGlyGlyGlyTrpGlyGln)5      (ProHisGlyGlyGlyTrpGlyGln)9--14                ?                                  Octapeptide/GOF                           RAN?

Disease-associated repeat sequence can include microsatellites (1--4 bp unit), minisatellites (6--64 bp unit), and megasatellites (several kb unit). GOF, gain-of-function; LOF, loss of function; RNA, toxic RNA. XXas or XXos = XX antisense or XX opposite strand. RAN, repeat associated non-ATG translation.

Information for the columns: Disorder, Gene, and Locus derived from Online Mendelian Inheritance in Man, OMIM (<http://www.ncbi.nlm.nih.gov/omim/>); McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University (Baltimore, MD); and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD). Repeat, Repeat size, Pathogenesis and Bi-directional transcription from López Castel et al. [@pgen.1002018-LpezCastel1].

Discovery of Repeat Associated Non-ATG Translation (RAN-Translation) {#s2}
====================================================================

The lab of Dr. Ranum has just published a paper that now reveals yet another surprise: RNA transcripts with expanded CAG repeats can be translated in the complete absence of a starting ATG, and this Repeat Associated Non-ATG translation (RAN-translation) occurs across expanded CAG repeats in all reading frames (CAG, AGC, and GCA) to produce homopolymeric proteins of long polyglutamine, polyserine, and polyalanine tracts [@pgen.1002018-Zu1] ([Figure 1](#pgen-1002018-g001){ref-type="fig"}). Constructs with expanded CTG tracts expressing CUG transcripts also show RAN-translation, which also occurs in all three frames (CUG, UGC, and GCU), to produce polyleucine, polycysteine ([Figure 1](#pgen-1002018-g001){ref-type="fig"}), and polyalanine. This counters the canonical requirements of translation initiation [@pgen.1002018-Sonenberg1]. RAN-translation occurs on expansion constructs that are integrated into the genome in cells and brains, as well as in tissues of transgenic mouse models of repeat diseases. Importantly, Ranum and colleagues show RAN-translation occurs in disease-relevant tissues of SCA8 and DM1 patients with CAG/CTG expansions.

Templates and Tissues for RAN-Translation {#s3}
=========================================

RAN-translation depends on repeat length to varying degrees for each reading frame. Constructs containing 15--20 CAG repeats did not express polyGln by RAN-translation, but constructs with 42--107 repeats did. PolyAla was robustly expressed with ∼100 repeats, moderately with ∼80 repeats, but not with 42 and 58 repeats. PolySer was detected with 58--107 but not 42 repeats. The length dependence for CTG constructs to RAN-translate polyleucine, polycysteine, and polyalanine is yet to be determined. Thus, RAN-translation is length dependent, and, for a given CAG tract length, polyAla is expressed at the highest levels followed by polyGln and polySer. Longer repeat tracts can express multiple RAN-translated homopolymeric proteins. Ranum and colleagues clearly demonstrated that all three RAN-translated proteins can be expressed simultaneously in a single cell.

RAN-translation was shown to occur in other disease-relevant sequence contexts, as constructs with flanking sequences from upstream of the CAG repeat from the Huntingtin (HD), Huntingtin-like 2 (HDL2), spinocerebellar ataxia type 3 (SCA3), or myotonic dystrophy type 1 (DM1) loci showed robust polyGln and polyAla and variable polySer expression in the absence of an ATG-start codon.

The surprising observation of RAN-translation on CAG and CUG tracts might also make one question what other repeat sequences may be permissive for RAN-translation. For example, might CGG or CCG repeats be RAN-translated? FXTAS, where premutation CGG expansions at the *FMR1* and the antisense CCG tracts from *FMR4* are transcribed ([Table 1](#pgen-1002018-t001){ref-type="table"}). Thus far, the evidence supports a role for a toxic-RNA mode of pathogenesis for FXTAS [@pgen.1002018-Oostra1]. RAN-translation across the CGG and CCG tracts would present polyArg, polyAla, polyGly, polyPro, polyArg, and polyAla runs as potential toxic entities for FXTAS.

Expansions of polyalanine and polyaspartic acid tracts can cause disease. At least nine diseases are caused by expansions of polyAla tracts in proteins and one is caused by expansion of an polyaspartic acid run ([Table 1](#pgen-1002018-t001){ref-type="table"}; see also [@pgen.1002018-LpezCastel1], [@pgen.1002018-Messaed1]). Instability in other amino acid runs has been hypothesized to be a source of disease [@pgen.1002018-Karlin1]. In the cases where the pathogenic path is known, both loss-of-function, gain-of-function, and dominant negative protein pathways are evident.

Might longer repeat units like tetranucleotide or pentanucleotide expansions be prone to RAN-translation? The possibility that the CUG present within the expanded CCUG tract of DM2 transcripts may lead to pathogenic RAN-translated products is worthy of consideration. RAN-translation across either the CCUG or CAGG tracts would produce a set of polymeric tetrapeptides, where each of the four possible reading frames would yield a distinct amino acid. CCUG, when RAN-translated, would produce CCU, GCC, UGC, and CUG, making repeated units of the tetrapeptide (ProAlaCysLeu)n. CAGG, when RAN-translated, would produce CAG, GCA, GGC, and AGG, making repeated units of the tetrapeptide (GlnAlaGlyArg)n. Notably, expansions of repeated amino acid tracts, as in the insertional expansion mutations of the octapeptide repeat of the prion protein ([Table 1](#pgen-1002018-t001){ref-type="table"}), are directly linked to prion disease: the normal PrP has four octapeptide segments, while expanded forms can have as many as nine additional octapeptide units. Genetic anticipation is evident in that prion disease onset correlates with octapeptide expansion size; with up to four extra units, the age of onset is \>60 years; with five to nine extra units, the age of onset is 30--40 years [@pgen.1002018-Stevens1].

Products of RAN-Translation {#s4}
===========================

What are the functions of tandem runs of amino acids and how might these pertain to disease? Many vertebrate proteins contain tandem runs of amino acids, with the vast majority being present in DNA/RNA metabolizing factors, where the homopolymers are thought to be involved in formation of large multi-protein complexes [@pgen.1002018-Faux1]. Such functions may be consistent with the ability of polyGln and polyAla proteins to form aggregates and may suggest a pathogenic role similar to aberration in the transcriptome or splicing, as with other repeat diseases [@pgen.1002018-LaSpada1].

Disease-specific tissues and cells showed RAN-translated homopolymeric proteins. Antibodies developed specifically to predicted amino acid sequences downstream of RAN-translated SCA8-polyAla and DM1 polyGln proteins. The SCA8-polyAla was detected in Purkinje cell soma and dendrites throughout the cerebellum in a SCA8 mouse model and cerebellar Purkinje cells of postmortem samples from SCA8 patients. Similarly, in DM1 mouse tissues and DM1 patient cardiac myocytes, leukocytes, and myblasts, polyGln nuclear aggregates were detected. These were not detected in non-disease or control mouse tissues. All of these observations support the presence of RAN-translated proteins in vivo and in patient tissues.

RAN-translation products may be toxic and may be linked to disease pathology. Zu et al. showed that cells transfected with CAG constructs that are RAN-translated to polyGln, polyAla, and polySer showed some signs of increased apoptosis, suggesting that RAN-translation products could be toxic to cells and may contribute to neurodegenerative disease symptoms. However, due to the toxicity outcome used (CAA versus CAG repeats as a measure of RAN-translation), toxicity is potentially confounded by any RNA-mediated toxicity. It is notable that polyAla has already been demonstrated to be toxic to cells and may contribute to several diseases ([Table 1](#pgen-1002018-t001){ref-type="table"}; see also [@pgen.1002018-Messaed1]). In the case of RAN-translation, it is unclear as to whether the polyAla, polySer, or PolyGln is the cause of the apparent toxicity, and to what degree this may contribute to disease.

Mechanism of RAN-Translation: Initiation, RNA-Structure, *cis*-Elements, and *trans*-Factors {#s5}
============================================================================================

The mechanism of RAN-translation initiation is unclear. The AUG-free CAG transcripts co-sedimented with the light polyribosomes. RAN-translation was sensitve to cycloheximide, which binds to ribosomes and inhibits tranlsation elongation. It would be interesting to learn the effect of other compounds (such as lactimidomycin or emetine) that can differentially affect initiation or elongation of translation [@pgen.1002018-SchneiderPoetsch1], [@pgen.1002018-Oleinick1] upon RAN-transation. RAN-translation is distinct from translational frameshifting previously reported for CAG tracts [@pgen.1002018-Gaspar1], [@pgen.1002018-Davies1]. Exactly where along the CAG tract initiation of RAN-translation occurs is unknown. Sites of initiation of RAN-translation may differ between repeats and reading frames. For example, RAN-translation of the CAG frame yielded predominantly a distinct polyglutamine protein band with a molecular weight similar to that of a protein initiated by an AUG start codon just upstream of the repeat [@pgen.1002018-Zu1], suggesting that RAN-translation initiated only at the start of the repeat sequence---either at the first CAG or at a non-AUG codon just upstream of the repeat. In contrast, RAN-translation of the GCA frame yielded a tightly spaced series of proteins, suggesting that initiation occurred at various points along the repeat. This was confirmed by mass spec analysis of the polyAla RAN products, which revealed a series of N-terminal peptides with varying numbers of alanine residues and a C-terminal fragment with the predicted C-terminal residues. Thus, initiation or RAN-translation may vary between repeat sequences.

RNA structure is likely to be critical to RAN-translation. Non-AUG initiation has been reported in a handful of mammalian genes arising at various codons, including ACG, CUG, GUG, and UUG [@pgen.1002018-Touriol1]. In all cases this is the result of methionine tRNA base pairing to a codon complimentary at only two bases. In contrast, Zu et al. reveal that RAN-translation does not appear to initiate via an N-terminal methionine [@pgen.1002018-Zu1]. An initiator Met-tRNA-independent form of non-AUG translation initiation is used by certain viruses [@pgen.1002018-Jan1]. These viruses use an internal ribosome entry site (IRES), which recruits ribosomes and initiates translation at non-AUG sites. Maintaining the base-pairing of the IRES pseudoknot stem-loop structures is necessary for translation initiation. Seemingly, the IRES structurally mimics the initiator tRNA, and manipulates the ribosome to allow for non-AUG initiation of translation. Future research will reveal whether the ability of expanded CAG transcripts to assume both intra-strand hairpins and multi-branched RNA structures [@pgen.1002018-Sobczak1] could be related to this viral mode of non-AUG Met-tRNA-independent translation initiation [@pgen.1002018-Jan1]. For example, the long r(CAG) tracts may permit folding into tRNA-like structures that permit self-priming of translation. Based upon the CNG tract length-dependence, Ranum and colleagues hypothesize that the initiation of RAN-translation may involve RNA hairpin structures [@pgen.1002018-Zu1], as long tracts of CAG and CUG repeats that can form hairpins and multi-branched RNA structures [@pgen.1002018-Sobczak1] can express homopolymers in the absence of ATG-starts repeat sequences, while repeat sequences that cannot form hairpins do not display RAN-translation. Further support for the role of a CAG/CUG hairpin comes from a report that a hairpin, previously used as a translational block, could, in some contexts of the *FMR1* transcript lacking a CGG tract, lead to translation initation at GUG codons in the hairpin stem [@pgen.1002018-Ludwig1]. Similar to the arrest of translation by the Kozak hairpin [@pgen.1002018-Kozak1], it was reported that expansions of either CGG repeats or CTG repeats (but not CAG repeats) suppressed translation in a tract length- and context- (5′UTR) dependent manner [@pgen.1002018-Feng1], [@pgen.1002018-Raca1]. Notably, the finding of context-dependent initiation in the Kozak hairpin [@pgen.1002018-Ludwig1], coupled with the hairpin-forming ability of CAG and CUG repeats, supports the possible role of hairpins in RAN-translation. Might non-repeat interruptions of expanded CNG repeats [@pgen.1002018-Sobczak1], [@pgen.1002018-Moseley2]--[@pgen.1002018-Braida1] that can disrupt intra-strand RNA conformations [@pgen.1002018-Sobczak1] affect RAN-translation? What other secondary sturctures permit RAN-translation? Curiously, in the absence but not the presence of an AUG, it was preliminarily suggested that a CUG codon downstream of an expanded in-frame CUG tract may initiate low levels of translation; however, this was not followed up [@pgen.1002018-Raca1]. The precise RNA structural features involved in RAN-translation need to be elucidated.

Repeat context may affect RAN-translation. Flanking RNA sequence may affect the capacity or efficiency of RAN-translation. For example, Zu et al. [@pgen.1002018-Zu1] found that brain RAN-translation in the polyglutamine frame was undetectable in the HD or SCA3 context, a little in the DM1 and HDL2 sequence, and a lot in the SCA8 context. Such effects may be due to the varied RNA structures assumed by the same CNG tract in different gene contexts [@pgen.1002018-Sobczak1]. Might the polyproline-encoding CCG tract immediately 3′ of the HD CAG tract or the polyglycine-encoding GGC tract adjacent to the SBMA CAG tract [@pgen.1002018-Andrew1], [@pgen.1002018-Irvine1] modulate RAN-translation?

Future Avenues---There Are Many {#s6}
===============================

Clearly, the canonical rules of translation do not apply to CAG•CTG expansion tracts since, in the absence of an ATG codon, expanded CAG and CTG trinucleotide repeats can express homopolymeric expansion proteins in all three frames ([Figure 1](#pgen-1002018-g001){ref-type="fig"}). RAN-translation may be a tissue-specific phenomenon, much like the instability of the repeats, which can vary by \>5,700 repeats between tissues [@pgen.1002018-LpezCastel2], [@pgen.1002018-Cleary1]. Production of antibodies to predicted downstream reading frames of each DNA strand of the expanded disease loci should reveal whether RAN-translation is possible at these loci. Further research is needed to reveal the true pathogenic role of any of the RAN-translation products. Understanding the mechanism of RAN-translation is going to be an area of active research.

Many new questions now arise with the discovery of RAN-translation. In addition to the immediate questions like "Do RAN-translated proteins contribute to disease pathology?" and "What is the mechanism of RAN-translation?" or "How many of the phenotypes in the cell and mouse models of trinucleotide repeat disease are the result of RNA-translated proteins rather than the supposed polyGln or CUG RNA?". Other questions include: "What other trinucleotide repeats (disease-associated or otherwise) might be RAN-translated?" or "Might non-trinucleotide repeats like tetranucleotide, pentanucleotide or other satellites undergo RAN-translation?" or "Might certain non-repetitive codons suffice to initiate RAN-translation?" or "Might the amino acid sequences downstream of the RAN-translated homopolymeric tracts contribute to disease?" or "What stop codons are used for the RAN-translated products?" or "Might there be a natural function of RAN-tranlslated proteins?" or "what proteins are involved in RAN-translation?" or "Might a depletion of amino acid pools be expected if RAN-translation exceeds the cells capacity, could this be related to the reduced plasma amino acids in either HD or DM1 patients to RAN-translation [@pgen.1002018-Reilmann1], [@pgen.1002018-Moxley1]?", and many others.

Conclusions {#s7}
===========

Validation of these initial and exciting observations of RAN-translation [@pgen.1002018-Zu1] and their extension to clinical disease in patients will make this a landmark paper that will reshape a large body of research on nucleotide repeat disorders, as well as re-focus our understanding of translational initiation and concepts of gene products/DNA stretch. The discovery of RAN-translation is likely to put many labs in many research areas in the RUNning for these answers.

![RUNning a RAN-gene.\
One DNA, two transcripts, seven possible reading frames, potentially nine toxic entities! Both CAG and CTG transcripts could be toxic [@pgen.1002018-Batra1], [@pgen.1002018-Li1], the AUG-initiated polyGln protein reading frame can be toxic, and each of the three reading frames from either the CAG or CUG transcript present six additional homopolymeric proteins, making a total of nine potentially toxic entities!](pgen.1002018.g001){#pgen-1002018-g001}
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